Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 476

1.

Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine.

Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy TE, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM.

Cancer Discov. 2018 Jun 14. pii: CD-18-0275. doi: 10.1158/2159-8290.CD-18-0275. [Epub ahead of print]

PMID:
29903880
2.

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.

Burt BM, Richards WG, Lee HS, Bartel S, Dasilva MC, Gill RR, Jaklitsch MT, Johnson BE, Swanson SJ, Bueno R, Sugarbaker DJ.

J Thorac Oncol. 2018 May 9. pii: S1556-0864(18)30594-X. doi: 10.1016/j.jtho.2018.04.032. [Epub ahead of print]

PMID:
29753120
3.

BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.

Planchard D, Johnson BE.

Arch Pathol Lab Med. 2018 Jul;142(7):796-797. doi: 10.5858/arpa.2018-0088-ED. Epub 2018 Apr 12. No abstract available.

PMID:
29648886
4.

Pooled RCTs: In postmenopausal women, hormone therapy for 6 to 7 years did not affect mortality at 18 years.

Johnson BE, Johnson CA.

Ann Intern Med. 2018 Jan 16;168(2):JC4. doi: 10.7326/ACPJC-2018-168-2-004. No abstract available.

PMID:
29335716
5.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators.

Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7.

PMID:
29217530
6.

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.

PMID:
28919011
7.

Negotiating sexual safety in the era of biomedical HIV prevention: relationship dynamics among male couples using pre-exposure prophylaxis.

Malone J, Syvertsen JL, Johnson BE, Mimiaga MJ, Mayer KH, Bazzi AR.

Cult Health Sex. 2018 Jun;20(6):658-672. doi: 10.1080/13691058.2017.1368711. Epub 2017 Sep 5.

PMID:
28872441
8.

A Pilot Randomized Controlled Trial of an Integrated In-person and Mobile Phone Delivered Counseling and Text Messaging Intervention to Reduce HIV Transmission Risk among Male Sex Workers in Chennai, India.

Mimiaga MJ, Thomas B, Biello K, Johnson BE, Swaminathan S, Navakodi P, Balaguru S, Dhanalakshmi A, Closson EF, Menon S, O'Cleirigh C, Mayer KH, Safren SA.

AIDS Behav. 2017 Nov;21(11):3172-3181. doi: 10.1007/s10461-017-1884-5.

PMID:
28831618
9.

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Pillai RN, Behera M, Berry LD, Rossi MR, Kris MG, Johnson BE, Bunn PA, Ramalingam SS, Khuri FR.

Cancer. 2017 Nov 1;123(21):4099-4105. doi: 10.1002/cncr.30869. Epub 2017 Jul 25.

PMID:
28743157
10.

<i>Hersilia</i> <i>aadi</i> Pravalikha, Srinivasulu &amp; Srinivasulu, 2014 a junior synonym of <i>Hersilia savignyi</i> Lucas, 1836 (Araneae: Hersiliidae).

Caleb JTD, Pravalikha GB, Johnson BE, Manyu M, Mungkung S, Mathai MT.

Zootaxa. 2017 Apr 18;4254(3):396-400. doi: 10.11646/zootaxa.4254.3.11.

PMID:
28609968
11.

Guideline: An expert panel found that calcium intake is safe from a cardiovascular perspective.

Johnson BE, Pagan ER.

Ann Intern Med. 2017 Feb 21;166(4):JC16. doi: 10.7326/ACPJC-2017-166-4-016. No abstract available.

PMID:
28241289
12.

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).

Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, Bonomi PD, Ellison DM, Eaton KD, Fritsch H, Munzert G, Johnson BE, Socinski MA.

Lung Cancer. 2017 Feb;104:126-130. doi: 10.1016/j.lungcan.2016.12.019. Epub 2016 Dec 30.

PMID:
28212994
13.

Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib.

Nishino M, Sacher AG, Gandhi L, Chen Z, Akbay E, Fedorov A, Westin CF, Hatabu H, Johnson BE, Hammerman P, Wong KK.

Eur J Radiol. 2017 Mar;88:15-20. doi: 10.1016/j.ejrad.2016.12.028. Epub 2016 Dec 26.

14.

Institutional implementation of clinical tumor profiling on an unselected cancer population.

Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE.

JCI Insight. 2016 Nov 17;1(19):e87062.

15.

Divide and Conquer to Treat Lung Cancer.

Johnson BE.

N Engl J Med. 2016 Nov 10;375(19):1892-1893. Epub 2016 Oct 8. No abstract available.

PMID:
27718875
16.

Transactional sex and the challenges to safer sexual behaviors: a study among male sex workers in Chennai, India.

Biello KB, Thomas BE, Johnson BE, Closson EF, Navakodi P, Dhanalakshmi A, Menon S, Mayer KH, Safren SA, Mimiaga MJ.

AIDS Care. 2017 Feb;29(2):231-238. Epub 2016 Jul 11.

17.

Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.

Redig AJ, Costa DB, Taibi M, Boucher D, Johnson BE, Jänne PA, Jackman DM.

JAMA Oncol. 2016 Sep 1;2(9):1240-2. doi: 10.1001/jamaoncol.2016.1304. No abstract available.

PMID:
27387964
18.

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.

Chong CR, Bahcall M, Capelletti M, Kosaka T, Ercan D, Sim T, Sholl LM, Nishino M, Johnson BE, Gray NS, Jänne PA.

Clin Cancer Res. 2017 Jan 1;23(1):204-213. doi: 10.1158/1078-0432.CCR-15-1601. Epub 2016 Jul 1.

19.

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6.

20.

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA.

Clin Cancer Res. 2016 Dec 15;22(24):6010-6020. Epub 2016 Jun 8.

Supplemental Content

Loading ...
Support Center